The startup specializes in the extraction of pure, viable exosomes from various biofluid sources, utilizing advanced separation techniques to ensure integrity and functionality. This process provides researchers and clinicians with high-quality exosome samples for applications in diagnostics and therapeutic development.
Funding
Funding not disclosed
Founders
Product
Problem
Researchers and clinicians require high-quality exosomes for diagnostics and therapeutic development, but current extraction methods may compromise exosome integrity and functionality. Inefficient separation techniques can lead to low yields and contamination, hindering downstream applications.
Solution
The startup provides a service specializing in the isolation of pure, viable exosomes from biofluids. Utilizing advanced separation techniques, the company ensures the extracted exosomes retain their native structure and biological activity. This offering enables researchers and clinicians to obtain consistent, high-quality exosome samples suitable for a range of applications, including biomarker discovery, drug delivery, and regenerative medicine. The service aims to overcome the limitations of traditional exosome isolation methods, delivering superior exosome preparations for reliable and reproducible results.
Target Audience
The primary customers are academic researchers, pharmaceutical companies, and biotech firms involved in exosome-based research and development.
Features
- Proprietary separation technology minimizing exosome damage during extraction
- Rigorous quality control assays to verify exosome purity, size distribution, and concentration
- Customizable exosome isolation protocols tailored to specific biofluid types and downstream applications
- Comprehensive characterization services, including protein and nucleic acid profiling